Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke
Alvarez-Sabín J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M
Published in International Journal of Molecular Sciences
Methodology
Two-year open-label follow-up of first-ever ischemic stroke patients receiving citicoline 1000 mg/day versus no citicoline, with serial neuropsychological testing and quality-of-life assessment.
Key Findings
Patients treated long-term with citicoline showed better attention-executive and temporal orientation scores and better quality of life at 2 years than untreated patients.
Conclusions
Long-term citicoline may attenuate post-stroke cognitive decline and improve quality of life.
Limitations
Open-label, non-randomised design with potential selection and observer bias; single-centre.
Supplements Studied
Patients treated long-term with citicoline showed better attention-executive scores and quality of life at 2 years.
Outcomes Measured
Long-term citicoline treatment prevented cognitive decline after a first ischemic stroke.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Investigator-initiated with support from Ferrer Grupo
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.